Abstract
Introduction: Studies are needed to understand the role of CD34 expressing cells with regard to efficient engraftment, especially in the adjuvant treatment of cancer. Materials and Methods: In this study we have used a modified method in our laboratory for routinely counting CD34+ cells. Unlysed whole blood samples were stained with the DNA-selective and cell membrane-permeant Vibrant DyeCycle Violet stain. Results: CD34+ cells exhibit a consistent and differential Vybrant Dye Cycle Violet staining pattern. Based on their different DCV intensity, we classified these subpopulations as CD34+/DCVhigh and CD34+/DCVlow cells. In general, DCVhigh cells are about 12-times brighter than DCVlow cells. Conclusion: DCV staining may be used to discriminate subsets of CD34+ cells similarly to other methods which have previously defined different functional properties that can be related to the characterization, resolution, and purification of primitive hematopoietic stem cells in combination with specific useful markers for multicolor flow cytometric measurements.
Keywords: CD34, flow cytometry, P-glycoprotein, Stem cells, Vybrant DyeCycle Violet.
Current Stem Cell Research & Therapy
Title:Vybrant DyeCycle Violet Stain Discriminates Two Different Subsets of CD34+ Cells
Volume: 11 Issue: 1
Author(s): Cristian Nunez-Espinosa, María D. Garcia-Godoy, Ines Ferreira, Juan G. Rios-Kristjansson, David Rizo-Roca, Laura G. Rico, Gerard Rubi-Sans, Carlos Palacio, Joan R. Torrella, Teresa Pages, Mike D. Ward, Gines Viscor and Jordi Petriz
Affiliation:
Keywords: CD34, flow cytometry, P-glycoprotein, Stem cells, Vybrant DyeCycle Violet.
Abstract: Introduction: Studies are needed to understand the role of CD34 expressing cells with regard to efficient engraftment, especially in the adjuvant treatment of cancer. Materials and Methods: In this study we have used a modified method in our laboratory for routinely counting CD34+ cells. Unlysed whole blood samples were stained with the DNA-selective and cell membrane-permeant Vibrant DyeCycle Violet stain. Results: CD34+ cells exhibit a consistent and differential Vybrant Dye Cycle Violet staining pattern. Based on their different DCV intensity, we classified these subpopulations as CD34+/DCVhigh and CD34+/DCVlow cells. In general, DCVhigh cells are about 12-times brighter than DCVlow cells. Conclusion: DCV staining may be used to discriminate subsets of CD34+ cells similarly to other methods which have previously defined different functional properties that can be related to the characterization, resolution, and purification of primitive hematopoietic stem cells in combination with specific useful markers for multicolor flow cytometric measurements.
Export Options
About this article
Cite this article as:
Nunez-Espinosa Cristian, Garcia-Godoy D. María, Ferreira Ines, Rios-Kristjansson G. Juan, Rizo-Roca David, Rico G. Laura, Rubi-Sans Gerard, Palacio Carlos, Torrella R. Joan, Pages Teresa, Ward D. Mike, Viscor Gines and Petriz Jordi, Vybrant DyeCycle Violet Stain Discriminates Two Different Subsets of CD34+ Cells, Current Stem Cell Research & Therapy 2016; 11 (1) . https://dx.doi.org/10.2174/1574888X10666150528152547
DOI https://dx.doi.org/10.2174/1574888X10666150528152547 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics
Current Pharmaceutical Biotechnology HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Edelfosine in Membrane Environment - the Langmuir Monolayer Studies
Anti-Cancer Agents in Medicinal Chemistry HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Drug-Induced Hypokalaemia
Current Drug Safety Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design Clinical Proteomics in Cancer Research
Current Proteomics Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Current Pharmaceutical Biotechnology Cell Proliferation and Cytotoxicity Assays
Current Pharmaceutical Biotechnology Gene Therapy for the Peripheral Nervous System: A Strategy to Repair the Injured Nerve?
Current Gene Therapy Cholangiocarcinoma Therapeutics: An Update
Current Cancer Drug Targets Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Current Cancer Drug Targets Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Sumoylation in Cellular Senescence and Aging
Current Molecular Medicine Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets